Liu LC, Chen YH, Lu DW. Overview of recent advances in Nano-Based ocular drug delivery. Int J Mol Sci. 2023;24(20):15352. https://doi.org/10.3390/ijms242015352.
Wu Z, Sun W, Wang C. Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis. Invest New Drugs. 2024;42(5):510–7.
Article PubMed CAS Google Scholar
Dave RS, Goostrey TC, Ziolkowska M, Czerny-Holownia S, Hoare T, Sheardown H. Ocular drug delivery to the anterior segment using nanocarriers: A mucoadhesive/mucopenetrative perspective. J Controlled Release: Official J Controlled Release Soc. 2021;336:71–88.
Organization WH. World Report On Vision. 2019.
Xu H, Rokohl AC, Ju X, Guo Y, Hou X, Fan W, et al. Global incidence and trends of ocular cancer: A bibliometric analysis. Adv Ophthalmol Pract Res. 2025;5(1):22–31.
Nowak MS, Romanowska-Dixon B, Grabska-Liberek I, Żurek M. Incidence and survival of ocular melanoma in National Cancer registry of Poland in 2010–2017. Advances in clinical and experimental medicine: official organ. Wroclaw Med Univ. 2022;31(6):615–21.
Mahendraraj K, Lau CS, Lee I, Chamberlain RS. Trends in incidence, survival, and management of uveal melanoma: a population-based study of 7,516 patients from the surveillance, epidemiology, and end results database (1973–2012). Clin Ophthalmol (Auckland, NZ). 2016;10:2113–9.
Sati A. Eye cancer market Size, share, industry trends, and forecasts (2024–2031). Consegic Business Intelligence; 2024 Oct. Available from: https://www.consegicbusinessintelligence.com/eye-cancer-market.
Huang Y, Guo Y. Quality of life among people with eye cancer: a systematic review from 2012 to 2022. Health Qual Life Outcomes. 2024;22(1):3.
Article PubMed PubMed Central Google Scholar
Ancona-Lezama D, Dalvin LA, Shields CL. Modern treatment of retinoblastoma: A 2020 review. Indian J Ophthalmol. 2020;68(11):2356–65.
Article PubMed PubMed Central Google Scholar
Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29(6):561–8.
Article PubMed PubMed Central Google Scholar
Wu M, Yavuzyigitoglu S, Brosens E, Ramdas WD, Kiliç E. Worldwide incidence of ocular melanoma and correlation with Pigmentation-Related risk factors. Investig Ophthalmol Vis Sci. 2023;64(13):45.
Fu Y, Xiao W, Mao Y. Recent advances and challenges in uveal melanoma immunotherapy. Cancers (Basel). 2022;14(13):3094. https://doi.org10.3390/cancers14133094.
Echegaray JJ, Bechrakis NE, Singh N, Bellerive C, Singh AD. Iodine-125 brachytherapy for uveal melanoma: A systematic review of radiation dose. Ocular Oncol Pathol. 2017;3(3):193–8.
Shields CL, Shields JA. Enucleation for uveal melanoma. In: Albert DM, Miller JW, Azar DT, Young LH, editors. Albert and Jakobiec’s principles and practice of ophthalmology. Cham: Springer International Publishing; 2022. pp. 7717–27.
Sheriff IHN, Karaa EK, Chowdhury T, Scheimberg I, Duncan C, Reddy MA, et al. Systemic adjuvant chemotherapy for advanced malignant ocular Medulloepithelioma. Eye. 2023;37(5):947–52.
Eteghadi A, Ebrahimi M, Keshel SH. New immunotherapy approaches as the most effective treatment for uveal melanoma. Crit Rev Oncol/Hematol. 2024;194:104260.
Sen M, Demirci H, Honavar SG. Targeted therapy in ophthalmic oncology: the current status. Asia-Pacific J Ophthalmol (Philadelphia Pa). 2024;13(2):100062.
Singh M, Durairaj P, Yeung J. Uveal melanoma: A review of the literature. Oncol Therapy. 2018;6(1):87–104.
Carvajal RD, Sacco JJ, Jager MJ, Eschelman DJ, Olofsson Bagge R, Harbour JW, et al. Advances in the clinical management of uveal melanoma. Nat Reviews Clin Oncol. 2023;20(2):99–115.
Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, et al. Overall survival benefit with Tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196–206.
Article PubMed CAS Google Scholar
Damato BE, Dukes J, Goodall H, Carvajal RD. Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma. Cancers. 2019;11(7):971. https://doi.org/10.3390/cancers11070971.
Stålhammar G. Delays between uveal melanoma diagnosis and treatment increase the risk of metastatic death. Ophthalmology. 2024;131(9):1094–104.
Atzpodien J, Terfloth K, Fluck M, Reitz M. Cisplatin, gemcitabine and Treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients. Cancer Chemother Pharmacol. 2008;62(4):685–8.
Article PubMed CAS Google Scholar
Pons F, Plana M, Caminal JM, Pera J, Fernandes I, Perez J, et al. Metastatic uveal melanoma: is there a role for conventional chemotherapy? - A single center study based on 58 patients. Melanoma Res. 2011;21(3):217–22.
Kalirai H, Damato BE, Coupland SE. Uveal melanoma cell lines contain stem-like cells that self-renew, produce differentiated progeny, and survive chemotherapy. Investig Ophthalmol Vis Sci. 2011;52(11):8458–66.
Kulbay M, Marcotte E, Remtulla R, Lau THA, Paez-Escamilla M, Wu KY, Burnier MN Jr. Uveal Melanoma: Comprehensive review of its pathophysiology, diagnosis, treatment, and future perspectives. Biomedicines. 2024;12(8):1758. https://doi.org/10.3390/biomedicines12081758.
Wu KY, Wang XC, Anderson M, Tran SD. Advancements in nanosystems for ocular drug delivery: A focus on pediatric retinoblastoma. Molecules. 2024;29(10):2263. https://doi.org/10.3390/molecules29102263.
You S, Luo J, Grossniklaus HE, Gou ML, Meng K, Zhang Q. Nanomedicine in the application of uveal melanoma. Int J Ophthalmol. 2016;9(8):1215–25.
PubMed PubMed Central Google Scholar
Dong Q, Jiang Z. Platinum–Iron Nanoparticles for Oxygen-Enhanced Sonodynamic Tumor Cell Suppression. Inorganics. 2024;12(12):331.
Wang Y, Xu Y, Song J, Liu X, Liu S, Yang N, et al. Tumor Cell-Targeting and Tumor Microenvironment-Responsive Nanoplatforms for the Multimodal Imaging-Guided Photodynamic/Photothermal/Chemodynamic Treatment of Cervical Cancer. Int J Nanomedicine. 2024;13(19):5837–58.
Wang B, Hu S, Zhou J, Zhou L, Xhwn ZY, Sun J, Guo XW, Wang HR, et al. Remineralization and bacterial inhibition of early enamel caries surfaces by carboxymethyl chitosan lysozyme nanogels loaded with antibacterial drugs. J Dent. 2025;152:105489.
Khiev D, Mohamed ZA, Vichare R, Paulson R, Bhatia S, Mohapatra S et al. Emerging Nano-formulations and nanomedicines applications for ocular drug delivery. Nanomaterials. 2021;11(1):173
Article PubMed PubMed Central CAS Google Scholar
Tavakoli S, Peynshaert K, Lajunen T, Devoldere J, Del Amo EM, Ruponen M, et al. Ocular barriers to retinal delivery of intravitreal liposomes: impact of vitreoretinal interface. J Controlled Release: Official J Controlled Release Soc. 2020;328:952–61.
Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: an overview. Int J Pharm. 2004;269(1):1–14.
Article PubMed CAS Google Scholar
Li S, Chen L, Fu Y. Nanotechnology-based ocular drug delivery systems: recent advances and future prospects. J Nanobiotechnol. 2023;21(1):232.
American Psychiatric Association. Anxiety disorders: DSM-5® selections. 1st ed. Arlington, VA: American Psychiatric Publishing; 2015.
Reimondez-Troitiño S, Csaba N, Alonso MJ, de la Fuente M. Nanotherapies for the treatment of ocular diseases. Eur J Pharm Biopharmaceutics: Official J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2015;95(Pt B):279–93.
Zeng H, Li J, Hou K, Wu Y, Chen H, Ning Z. Melanoma and Nanotechnology-Based treatment. Front Oncol. 2022;12:858185.
Article PubMed PubMed Central Google Scholar
Zielińska A, Carreiró F, Oliveira AM, Neves A, Pires B, Venkatesh DN, Durazzo A, Lucarini M, Eder P, Silva AM, Santini A, Souto EB. Polymeric nanoparticles: Production, characterization, toxicology and ecotoxicology. Molecules. 2020;25(16):3731. https://doi.org/10.3390/molecules25163731.
Ko MJ, Min S, Hong H, Yoo W, Joo J, Zhang YS, et al. Magnetic NPs for ferroptosis cancer therapy with diagnostic imaging. Bioactive Mater. 2024;32:66–97.
Sun L, Qi J, Ding L, Wang Z, Ji G, Zhang P. Ultrasound-triggered nano delivery of lenvatinib for selective immunotherapy treatment against hepatocellular carcinoma. Sci Rep. 2024;14(1):27395.
Article PubMed PubMed Central CAS Google Scholar
García-Díaz M, Foged C, Nielsen HM. Improved insulin loading in poly(lactic-co-glycolic) acid (PLGA) NPs upon self-assembly with lipids. Int J Pharm. 2015;482(1–2):84–91.
Comments (0)